
The $2.65 billion merger between Patheon and DSM’s pharma business has completed, creating a new privately-held company called DPx. The …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

